Raymond James Financial
CLDX icon

Raymond James Financial’s Celldex Therapeutics CLDX Stock Holding History

Raymond James Financial’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-281
Closed -$5.72K – 5300
2025
Q2 		$5.72K Buy
+281
New +$5.47K ﹤0.01% 6131

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Raymond James Financial's CLDX Position: Q3 2025 in Review

Raymond James Financial sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 281 shares — an estimated $5.72K sold.

Raymond James Financial first reported a position in CLDX in Q2 2025 and held it in 1 quarter. The position peaked at $5.72K in Q2 2025. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Raymond James Financial reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 281 Celldex Therapeutics shares in Q3 2025, an estimated $5.72K.
  • Raymond James Financial first reported a position in Celldex Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Celldex Therapeutics position peaked at $5.72K in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.